233 related articles for article (PubMed ID: 27259590)
21. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
22. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
23. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
24. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Jabbour E; Kantarjian H; O'Brien S; Shan J; Quintas-Cardama A; Faderl S; Garcia-Manero G; Ravandi F; Rios MB; Cortes J
Blood; 2011 Oct; 118(17):4541-6; quiz 4759. PubMed ID: 21803854
[TBL] [Abstract][Full Text] [Related]
25. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Cortes JE; Kantarjian HM; Goldberg SL; Powell BL; Giles FJ; Wetzler M; Akard L; Burke JM; Kerr R; Saleh M; Salvado A; McDougall K; Albitar M; Radich J;
J Clin Oncol; 2009 Oct; 27(28):4754-9. PubMed ID: 19720924
[TBL] [Abstract][Full Text] [Related]
26. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
[No Abstract] [Full Text] [Related]
27. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
28. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
30. High
Vigneri P; Stagno F; Stella S; Cupri A; Forte S; Massimino M; Antolino A; Siragusa S; Mannina D; Impera SS; Musolino C; Malato A; Mineo G; Tomaselli C; Murgano P; Musso M; Morabito F; Molica S; Martino B; Manzella L; Müller MC; Hochhaus A; Raimondo FD
Clin Cancer Res; 2017 Dec; 23(23):7189-7198. PubMed ID: 28928163
[No Abstract] [Full Text] [Related]
31. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
[TBL] [Abstract][Full Text] [Related]
32. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Takahashi N; Miura I; Kobayashi Y; Kume M; Yoshioka T; Otane W; Ohtsubo K; Takahashi K; Kitabayashi A; Kawabata Y; Hirokawa M; Nishijima H; Ichinohasama R; Decoteau J; Miura AB; Sawada K
Int J Hematol; 2005 Apr; 81(3):235-41. PubMed ID: 15814334
[TBL] [Abstract][Full Text] [Related]
33. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
DeAngelo DJ; Chen L; Guerin A; Styles A; Giguere-Duval P; Wu EQ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):245-51. PubMed ID: 24393622
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
35. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
[TBL] [Abstract][Full Text] [Related]
36. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Ravandi F; Jabbour E; Shan J; Cortes J
Cancer; 2012 Jun; 118(12):3116-22. PubMed ID: 22370904
[TBL] [Abstract][Full Text] [Related]
37. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
39. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
[TBL] [Abstract][Full Text] [Related]
40. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]